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INTRODUCTION 
 
 Recombinant bovine somatotropin (rbST), the first recombinant protein approved for 
use in production animals, has received unprecedented scrutiny. In the US this included 
the traditional evaluation by FDA as well as public hearings, science evaluations and 
legislative reviews (Bauman, 1992). It has  been 20 years since the introduction of rbST 
( POSILAC ®) into the dairy industry of several countries, and to date in the US an 
estimated 35 million dairy cows have received Posilac supplements, the commercial 
formulation of rbST (personal communication, R. Cady, Elanco). 
 
 Recently, two studies were conducted to update the evaluation of the human safety 
and animal performance and welfare literature published since the approval of rbST, 
(Collier and Bauman, 2014; St Pierre et al. 2014). The following is a synopsis of those 
papers. 
 
HUMAN SAFETY 
 
 The Joint FAO/WHO Expert Committee on Food Additives (JECFA) is an 
international expert scientific committee administrated jointly by FAO of the United 
Nations and the World Health Organization. JEFCA reviewed the human safety of rbST 
at their 40th conference in 1993 and the 50th conference in 1998 and concluded both 
times that "the lack of oral activity of rbSTs and insulin-like growth factor I (IGF-1) and 
the low levels and non-toxic nature of the residues of these compounds, even at 
exaggerated doses, results in an extremely large margin of safety for humans 
consuming dairy products from rbST-treated cows.” Based on this the committee 
concluded that there was no need to establish an “acceptable daily intake” or “minimum 
residue levels”, and that the use of rbST “does not represent a hazard to human health” 
(JECFA, 1993; JECFA, 1998). In early 2013 JECFA announced that they would be re-
evaluating rbST at the 78th JEFCA Conference and requested new data and 
information related to human health and the use of rbST. Listed topics of particular 
interest were: the possible increased use of antibiotics to treat mastitis in cows; 
possibility of increased levels of IGF1 in the milk of cows treated with rbST; potential 
effects of rbST on the expression of certain viruses in cattle; and possibility that 
exposure of human neonates and young children to milk from rbST-treated cows 
increases health risks, for example development of insulin-dependent diabetes mellitus. 
 
 
 
 
Milk Antibiotic Residues 
 
 Antibiotics are used by the dairy industry to treat mastitis, and residues occur when 
the milk is saved before the antibiotics have fully cleared. Major factors affecting the 
incidence of mastitis are related to environmental conditions and management 
practices. There is also a small increase in mastitis incidence, expressed on a per cow 
basis, as milk production increases, and FDA concluded that the use of rbST was also 
associated with an increase in the relative risk of mastitis. The 50th JECFA Conference 
also evaluated the relationship between rbST use and the potential for milk antibiotic 
residues. They concluded “that the use of rbST will not result in a higher risk to human 
health due to the use of antibiotics to treat mastitis and that the increased potential for 
drug residues in milk could be managed by practices currently in use by the dairy 
industry and by following label directions for use” (JECFA, 1998). The following 
represents results from commercial use in the US and related scientific publications 
since the 50th JECFA. 
 
 The national data summary of milk antibiotic residue violations provides some insight 
on the potential impact of rbST use. The National Milk Drug Residue Data Base 
(NMDRD) is a voluntary industry reporting program but State Regulatory Agencies 
report all data received to the National Conference on Interstate Milk Shipments 
(NCIMS; (http://www.ncims.org/). The system includes all milk, Grade “A” and non-
Grade “A”, commonly known as manufacturing grade. Grade A milk represents 
approximately 95% of the US milk supply and is regulated through the NCIMS by the 
State Regulatory Agencies. Manufacturing grade milk is under the direction of the 
Regulatory Agencies in States where it is produced. In 1995 the industry testing 
program switched to a more sensitive test for antibiotics and there are continuing efforts 
to ensure uniform and accurate reporting of drugs and test methods among States. 
 
 The pattern of milk antibiotic residue violations for the US dairy industry from 1995 to 
2012 is shown in Figure 1 (adapted from NMDRD, 2013). The percent of bulk milk tank 
trucks testing positive for antibiotic residues has steadily declined since 1996 and in 
2012 was less than one-fifth of the level detected in 1995 (0.100% in 1995 versus 
0.017% in 2012). Thus, there is no evidence of increased human risk for exposure to 
milk antibiotic residues related to the use of rbST in the U.S. dairy industry over the last 
18 years. 
 
 Milk somatic cell count (SCC) is a measure of milk quality and a reflection of 
mammary health. SCC refers to the number of white blood cells, secretory cells, and 
squamous cells per milliliter of raw milk. Somatic cells from an infected quarter of the 
udder are present in in milk at much higher numbers and these are predominately 
leukocytes or white blood cells including neutrophils (major form), macrophages and 
lymphocytes. Thus, SCC values provide insight related to milk quality and subclinical 
mastitis. 
 
 
 The USDA’s Animal and Plant Health Inspection Service Centers for Epidemiology 
and Animal Health, in collaboration with USDA’s Agricultural Marketing Service and the 
National Mastitis Council’s Milk Quality Monitoring Committee, monitor the US milk 
quality using bulk-tank somatic cell count (BTSCC) data provided by 4 of the Nation’s 
10 Federal Milk Marketing Orders. 
 
 As reported by Collier and Bauman (2014), the US pattern for milk BTSCC declined 
steadily from 316.000 cells per mL of milk in 2001 to 224,000 cells/mL in 2010 and 
206,000 cells/mL in 2011 (USDA, 2013). Thus, there is no evidence for an increase in 
the SCC for the US dairy herd over the interval of POSILAC use. Rather, the decline in 
SCC over the last decade indicates an improvement in milk quality and mammary 
health. van Schiak et al. (2002) demonstrated that “high SCC is a generic predictor of 
poor milk quality.” Herds with 200,000 cells per ml of milk or less had the lowest 
incidence of antibiotic residues. Therefore, the inference from SCC data over the last 15 
years is that the potential human threat from milk antibiotic residues has declined 
dramatically. 
 
 
Figure 1. Percent of Bulk Milk Tankers Positive for Antibiotic Residues – 1995 to 2012 
 
Insulin-like Growth Factors in Milk 
 
 The 50th Conference Report (JEFCA, 1998) concluded “that any increase of IGF-I in 
milk from rbST-treated cows is orders of magnitude lower than the physiological 
amounts produced in the gastrointestinal tract as well as in other parts of the body”. The 
report further concluded that “the intake of IGF-I (from milk) will not increase either 
locally in the gut or systemically. Consequently, the potential for IGF-I to promote tumor 
growth will not increase when milk from rbST-treated cows is consumed, resulting in no 
appreciable risk for consumers” (JECFA, 1998). 
 
 Since the 1998 JECFA Report, the absorption of orally consumed IGF-I has been 
directly examined in humans, specifically premature neonates and young adults; results 
are convincing and provide no evidence that orally consumed IGF-I is absorbed in 
humans (Mero et al., 2002; Corpeleijn et al., 2008). IGF-I plays many important roles 
and almost every tissue in the body synthesizes IGF-I. While the IGF system is critical 
for normal growth and development, it can also play a key role in the survival and 
growth of malignant cells. Although outside the purview of this report, there has been a 
related interest in the possible role of milk consumption on the risk for various types of 
cancers. Milk is known to contain a number of components which have anticarcinogenic 
effects when tested in studies with animal biomedical models (e.g. Parodi, 2007). 
Likewise, epidemiology studies indicate that the consumption of milk and dairy products 
reduces the risk against many types of cancer including bladder, breast, and colon 
cancers (e.g. reviews by Kliem and Givens, 2011; Rice et al., 2013). An exception is 
prostate cancer where an overview of studies suggests a very modest positive 
association between milk consumption and the risk of prostate cancer; several 
mechanisms to explain this effect are being actively investigated (see review by Parodi, 
2009). Overall, results since the 50th JECFA have provided additional evidence of the 
minimal effects of rbST on milk concentrations of IGF-I and further demonstrated a lack 
of absorption of orally consumed IGF-I in premature neonates and young adults. 
 
Bovine Somatotropin and Viruses 
 
 The 1998 JEFCA Conference concluded that there was no evidence that rbST 
affects the expression of BLV, a lentivirus, based on studies with a goat model that used 
caprine arthritis encephalitis virus. They also noted that BLV was destroyed by 
simulated pasteurization conditions when milk is heated to 60°C for 30 seconds and that 
there was no evidence of human susceptibility to ruminant retroviruses (JECFA, 1998). 
No new information on effect of rbST on expression of retroviruses in ruminants has 
been published since the 1998 Conference. However, several new research models 
have been developed to study retroviruses (see review by El Hajj et al., 2012) which 
may provide additional information in the future. The important role of somatotropin in 
the immune system has been clearly established (see review by Kelley et al., 2007). 
Additionally, research has demonstrated that human somatotropin increases immune 
system function in HIV infected people (e.g. Napolitano et al., 2008; Tesselaar and 
Miedema, 2008) and somatotropin administration to chickens increased resistance to 
Marek’s virus (Liu et al., 2001). Overall, there is no evidence of increased expression of 
retroviruses in cattle treated with rbST or that retroviruses in cattle would pose a risk to 
human health. 
 
Bovine Somatotropin and Diabetes Risk 
 
 Nutrients derived from the consumption of milk are important for normal growth and 
development in children, and in health maintenance and a reduction in risk for chronic 
diseases in adults. Past research on insulin-dependent diabetes mellitus has focused 
on diet and the concept that early introduction of complex foreign proteins might be a 
risk factor for β-cell autoimmunity thereby leading to Type 1 diabetes. Some reports 
suggested early infant exposure to cow’s milk protein was a predisposing factor that 
might increase the risk of Type 1 diabetes, whereas other observations found no 
causality. Nevertheless, the 1998 Conference concluded that the use of rbST would not 
impact the risk of Type1 diabetes because milk composition is unaltered (JECFA, 
1998). 
 
 Milk protein was a major research focus in early work, but to date no specific dietary 
factor or food component has been shown to be an unequivocal risk factor for β-cell 
autoimmunity. Rather, recent research has suggested a much broader range of putative 
mechanisms in genetically susceptible individuals. Examples of purposed putative 
mechanisms include viral, microbial, diet-related, anthropometric and psychosocial 
factors (e.g. see reviews by Eringsmark et al., 2013; Pugliese, 2013). Overall, our 
review found no new data suggesting increased health risks in children or adults 
consuming milk and dairy products from rbST-supplemented cows. Milk composition is 
affected by many factors including genetics, stage of lactation, breed, diet, environment, 
and season, and these factors affect milk composition in an identical manner in rbST-
supplemented cows (Bauman, 1992). 
 
 In addition to providing essential nutrients, there is increasing recognition that 
consumption of milk and dairy products is associated with improvement in health 
maintenance and the prevention of chronic diseases. Chronic diseases where a 
moderate health benefit is observed from the consumption of milk and dairy products 
include a reduced risk of Type 2 diabetes, improved bone health, lower blood pressure, 
and reduced risk of cardiovascular disease (e.g. see summaries in Elwood et al., 2008; 
Kliem and Givens, 2011; Rice et al., 2013). Given the composition of milk is not altered 
by the use of rbST, the beneficial effects of dairy products on health maintenance and 
reductions in risk of chronic diseases should not be affected. 
 
ANIMAL EFFICIENCY AND WELFARE 
 
 In order to update the evaluation of the safety and efficiency of rbST-Zn an expert 
panel made up of a data manager and project coordinator, a professional statistician, 
and six domain experts was assembled (St. Pierre et al., 2014). The evaluation involved 
a set of meta-analyses using peer-reviewed research data from scientific publications or 
regulatory agency reports where rbST-Zn was used according to label. Data from 
studies involving off-label use of rbST-Zn or studies that used unapproved formulations 
of rbST were excluded. The data were collected for the meta-analysis in the following 
manner. An extensive literature search was conducted on PubMed (U.S. National 
Library of Medicine, U.S. National Institute of Health, Bethesda, MD), Agricola (National 
Agriculture Library, U.S. Department of Agriculture, Beltsville, MD), Web of Science 
(Thomson Reuters Science, New York, NY), and CAB Direct (CAB International, 
Wallingford, UK) using the following combination of search terms: bST, rbST, 
sometribove, sometribove zinc, Posilac, bovine somatotropin or bovine growth 
hormone. Potential studies were identified and abstracts were obtained. All studies that 
were not conducted using rbST-Zn or that clearly did not report results pertinent to the 
analyses (e.g., dairy market analyses) were immediately discarded. The remaining 
studies were numbered and their corresponding full papers were obtained. Twenty-six 
studies met the criteria and data were drawn from them to form a meta-database. 
Specific details of the methodology for the meta-analysis can be found in St. Pierre et 
al. (2014) and results of this analysis are presented in the following sections. 
 
Milk Yield and Composition 
 
 Seven variables were analyzed to characterize the milk and milk composition 
responses to rbST: milk yield, percent milk fat, percent milk true protein, percent 
lactose, 3.5% fat-corrected milk yield, fat yield and protein yield. Except for the 
percentage of lactose in milk, responses across studies were heterogeneous (P < 0.10), 
indicating that unidentified factors associated with individual studies affect the 
magnitude of the response. 
 
 Results indicated that yield of milk and milk components were all increased by rbST. 
Milk yield (+4.00 kg/d) and 3.5% fat corrected milk (+4.04 kg/d) were increased by about 
15% over unsupplemented cows (Table 1). However, milk composition for fat (P = 
0.088), protein (P = 0.067), and lactose (P = 0.264) were not affected by rbST (Table 1). 
Thus, yield of these components increased in parallel to milk production with daily yields 
of fat (P < 0.001) and protein (P < 0.001) being increased by an average of 0.144 and 
0.137 kg/d, respectively. 
 
Udder Health 
 
 Tests for heterogeneity indicated significance for both milk log SCC (P < 0.001) and 
mastitis incidence rate (P < 0.035); thus, unidentified factors associated with individual 
studies affect the observed values. In the case of SCC, the control group averaged 
nearly 100,000 SCC/mL and there was no effect of rbST supplements (P = 0.540; Table 
1). Likewise, the mastitis incidence rate was not different between the control and rbST-
supplemented groups (P < 0.122; Table 2). Environmental and management factors are 
the major causes of mastitis. In addition genetic studies have demonstrated a small 
positive relationship between in mastitis risk and milk production. However, high 
producing herds are better managed so that effects of increased milk production are 
minimized or negated (Hogan and Smith, 2012). 
 
Body Condition 
 
 Data for body condition score (BCS) were available for 15 studies, and the test for 
heterogeneity of responses among studies approached significance (P = 0.104). The 
BCS data used in the meta-analysis consisted of the BCSs obtained during and after 
rbST administration. Cows treated with rbST had a significantly (P = 0.037) lower mean 
BCS than did the control cows with the difference being –0.064 ± 0.031 points (mean ± 
SE; Table 1). Published studies indicate that 1 unit of BCS represents about 50 kg body 
weight, so the difference in BCS for the rbST treated cows represents about 3.2 kg. 
While significant, this difference would not be visually detected and is about equivalent 
to the change in body weight associated with a typical feeding or drinking episode for a 
dairy cow. 
 
Lameness 
 
 Data regarding the number of cows that were clinically lame are presented in Table 
1. Where possible the data regarding foot lesions were separated into two categories - 
lameness lesions and traumatic lesions. Lameness lesions are lesions that directly 
cause clinical lameness (e.g. laminitis, sole ulcers or digital dermatitis) whereas 
traumatic lesions are lesions that rarely cause or result in lameness (e.g. mechanically 
induced skin lesions) (Shearer et al., 2012). The test for heterogeneity was not 
significant for any of the 3 outcome variables (P = 0.999). Incidence rates for cows that 
were clinically lame, had lameness lesions, or had traumatic lesions did not vary 
significantly between cows that were and were not treated with rbST-Zn (P = 0.991; 
Table 1). 
 
Table 1. Estimates of responses to rbST and associated statistics from the meta-
analyses of continuous traits1. 
Variables 
Number 
of 
Studies 
Mean 
of 
Control 
Cows 
Response 
Estimate 
Standard 
Error of 
Estimate 
P 
Value 
95% 
Lower 
CL5 
95% 
Upper 
CL 
Milk Production and composition 
Milk yield (kg/d) 
 
15 
 
27.2 
 
4.00 
 
0.404 
 
<0.001 
 
3.21 
 
4.79 
Fat (%) 13 3.64 -0.073 0.043 0.088 -0.156 0.011 
Protein (%) 13 3.15 0.025 0.013 0.067 -0.001 0.051 
Lactose (%) 11 4.82 0.023 0.021 0.264 -0.017 0.063 
3.5% FCM (kg/d) 13 29.2 4.04 0.410 <0.001 3.24 4.84 
Fat yield (kg/d) 13 1.08 0.144 0.021 <0.001 0.104 0.185 
Protein yield (kg/d) 13 0.86 0.137 0.018 <0.001 0.101 0.173 
Reproduction (all parities) 
Days open 
 
5 
 
104.2 
 
-0.21 
 
4.18 
 
0.960 
 
-8.39 
 
7.98 
Services per conception 4 1.66 -0.25 0.162 0.121 -0.57 0.07 
Udder health 
Log10 somatic cell count 
 
9 
 
4.996 
 
-0.034 
 
0.055 
 
0.540 
 
-0.141 
 
0.074 
Lameness and lesions 
Clinical lameness 
 
7 
 
0.38 
 
0.13 
 
1.14 
 
0.991 
 
-2.18 
 
2.21 
Lameness lesions 3 1.12 0.32 29.2 0.991 -55.4 56.0 
Traumatic lesions 5 0.11 0.093 7.59 0.991 -15.5 15.7 
Body condition 
Body condition score3 
 
15 
 
3.31 
 
-0.064 
 
0.031 
 
0.037 
 
-0.124 
 
-0.004 
Culling 
Culling density4 
 
6 
 
4.64 
 
0.603 
 
0.633 
 
0.341 
 
-0.637 
 
1.018 
1From St. Pierre et al. (2014). 
2Expressed as incidence rate per 1,000 cow-days at risk. 
3Body condition score is expressed on a 1 to 5 scale, with 5 being severely over-conditioned. 
4Culling density is expressed as incidence rate per 10,000 cow-days at risk. 
5CL = confidence limit. 
6Log10 somatic cell count of 4399 = 97,734 somatic cells/mL. 
 
 
 
 
Reproduction 
 
A significant 5.4% improvement in pregnancy proportion was observed in the rbST 
supplemented cows for the first two breeding cycles after the voluntary wait period (P < 
0.007; Table 2). When compared over the full length of the trial, the pregnancy 
proportion was reduced 5.5% for the group receiving rbST (P < 0.048; Table 2), a 
reduction that was likely due to reduced estrous behavior. There was no effect of rbST 
on fetal loss, days open, services per conception, twinning, or cystic ovaries, Tables 1 
and 2. 
 
Table 2. Estimates of responses to rbST expressed as odds ratios and associated 
statistics from the meta-analyses of non-continuous traits1. 
Variables 
Rate of 
Control 
Cows 
Estimates 
of 
Odds Ratio 
P 
Value 
95% 
Lower 
CL4 
95% 
Upper 
CL 
Reproduction, all parities 
Pregnancy rate in LRP2 0.291 1.281 0.007 1.072 1.530 
Pregnancy rate in ERP3 0.761 0.753 0.048 0.568 0.997 
Fetal losses rate 0.115 1.065 0.650 0.812 1.397 
Twinning rate 0.065 1.107 0.679 0.685 1.787 
Cystic ovaries rate 0.065 1.171 0.425 0.795 1.725 
Udder health 
Mastitis incidence rate 0.174 1.249 0.122 0.942 1.655 
1From St. Pierre et al. 2014 
2Limited response period (first and second AI inseminations. 
3Extended response period (full duration of the trial). 
4CL = confidence limit. 
 
Summary of Meta-Analysis 
 
 Results of the meta-analysis carried out by St-Pierre et al. (2014) indicated that 
administration of the commercially available rbST formulation to lactating dairy cows 
according to FDA-approved label directions resulted in an increase in milk, fat, and 
protein yields with no unmanageable adverse effects on milk composition (percentages 
of fat, protein, and lactose in milk), udder health, reproduction, body condition, 
lameness, or culling. These findings are contrary to a meta-analysis commissioned by 
Health Canada (Dohoo et al., 2003), but are in line with conclusions of various FDA 
evaluations (US FDA, 2014a; US FDA 2014b), numerous scientific reviews (e.g. 
Crooker et al., 1991; Bauman, 1992), and large-scale studies conducted on commercial 
dairy operations (e.g. Ruegg et al.1998; Bauman et al., 1999; Collier et al. 2001). 
 
CONCLUSIONS 
 
 Recombinant bovine somatotropin is a technology that allows a liter of milk to be 
produced using fewer nutrients and a lower carbon footprint. Twenty years of 
commercial use of rbST in the US provides the backdrop for an updated review of the 
outcome of use on human safety and animal efficacy and welfare. A review of recent 
advancements in scientific knowledge confirms earlier conclusions and provides no 
evidence of possible human health issues related to the use of rbST by the dairy 
industry. In the case of animal well-being, results indicated that rbST-Zn administration 
to dairy cows effectively increases milk production with no adverse effects on cow well-
being. Overall, these results and 20 years’ experience demonstrate that commercial use 
of rbST by dairy producers is safe, effective, and allows for the production of 
wholesome dairy products. 
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